Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Johnson & Johnson Pharamceutical Research & Development, L.L.C
Femme et Homme Max 99 ans
Johnson & Johnson Pharamceutical Research & Development, L.L.C
MAJ Il y a 4 ans
Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain from Low Back Pain or Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the safety profile of CG5503 base IR 50 mg or 100 mg taken every 4 to 6 hours as needed over the long term exposure of 90 days
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharamceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease
The primary objective of this study is to determine the efficacy of CG5503 immediate-release (IR) using the sum of pain intensity difference (SPID) over 5 days compared with placebo, and to assess the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations